Nuvia wPrime 2A Media
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Nuvia wPrime 2A Media, a scalable weak anion exchange and hydrophobic interaction (AEX-HIC) mixed-mode chromatography resin for small- to large-scale biomolecule purification. Bio-Rad's partners that aided in the resin’s development successfully used the resin to remove host cell proteins, high and low molecular weight aggregates and impurities, and DNA from monoclonal and bispecific antibodies, and adeno-associated virus.
Built upon Bio-Rad's Nuvia bead technology, Nuvia wPrime 2A Media features a polyacrylamide (acrylamide polymer) base bead that can be used for laboratory- and small-scale purification workflows, as well as for pilot-scale bioproduction and manufacturing-scale downstream processing. Bio-Rad’s Nuvia resins are designed to have minimal non-specific binding reactions, due to the hydrophilic nature of the bead polymer, and maintain a constant dynamic binding capacity over a wide range of flow rates. The Nuvia bead allows for fast mass transfer, is chemically and mechanically stable over a wide range of conditions and is easy to pack.
Developed in collaboration with Bio-Rad’s partners in industrial biotherapeutic production, Nuvia wPrime 2A Media provides a wide purification design space. The charge state of the resin’s functional ligand can be modulated by the pH of the buffer, enabling the purification of otherwise difficult-to-separate biomolecules from other impurities.
"Bio-Rad is committed to developing innovative chromatography resins for a wide variety of customer needs, and to advancing the efforts of researchers and therapy manufacturers alike in saving lives," said Diab Elmashni, Director, Process Chromatography Business at Bio-Rad Laboratories. "As a leader in multimodal chromatography technology, Bio-Rad’s Nuvia and CHT™ Ceramic Hydroxyapatite families of resins and media are integral to pharmaceutical development and industrial-scale purification for many customers worldwide This new resin is unique to the market and addresses customer requests for a scalable, weak anion exchange and hydrophobic interaction mixed-mode resin."
Visit bio-rad.com/wPrime2A to learn more about Nuvia wPrime 2A Media, and to request samples.
BIO-RAD and CHT are trademarks of BIO-RAD Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and, our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications
Dr. Maria Spyrou
+44 (0) 7707 049 640
maria.spyrou@zymecommunications.com